113 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
11
Influence of polar side chains modifications on the dual enkephalinase inhibitory activity and conformation of human opiorphin, a pain perception related peptide.
Institute of Advanced Chemistry of Catalonia (Iqac-Csic)
4
Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.
Pharmaleads
18
New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
Pharmaleads
2
Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor.
University of Siena
10
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.
University of Lille
19
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.
Glaxosmithkline
10
Dual metalloprotease inhibitors. III. utilization of bicyclic and monocyclic diazepinone based mercaptoacetyls
TBA
12
Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls
TBA
15
Dual metalloprotease inhibitors. I. constrained peptidomimetics of mercaptoacyl dipeptides
TBA
33
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
33
Novelß-amino acid derivatives as inhibitors of cathepsin A.
Sanofi-Aventis Deutschland
21
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.
Wroclaw University of Technology
8
Proposed Bioactive Conformations of Opiorphin, an Endogenous Dual APN/NEP Inhibitor.
TBA
22
Structure-activity relationship study of opiorphin, a human dual ectopeptidase inhibitor with antinociceptive properties.
Institute of Advanced Chemistry of Catalonia (Iqac-Csic)
95
Designed multiple ligands. An emerging drug discovery paradigm.
Organon Laboratories
9
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
University Institute of Pathology
6
Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.
Institute of Biomedical Chemistry of Russian Academy of Medical Sciences
4
Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs.
University of Paris
34
Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.
University of Paris
28
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
Novartis Institute For Biomedical Research
26
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
F. Hoffmann-La Roche
33
Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme.
University of Paris
37
Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Novartis Pharmaceuticals
40
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
University of Paris
30
Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
University of Paris
25
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
Ciba-Geigy
24
Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.
Berlex Laboratories
22
N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.
Ciba-Geigy
21
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
University of Paris
10
Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.
Ciba-Geigy
23
Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation.
University of Paris
13
Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes.
Ua 498 Cnrs
12
Synthesis and biological evaluation of phosphonamidate peptide inhibitors of enkephalinase and angiotensin-converting enzyme.
TBA
20
New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.
TBA
9
New carboxyalkyl inhibitors of brain enkephalinase: synthesis, biological activity, and analgesic properties.
TBA
17
Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11
TBA
18
Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11
TBA
14
Synthesis and evaluation of 2-(biphenylmethyl)glutaric acid amide derivatives as neutral endopeptidase inhibitors.
TBA
14
Potent inhibitors of neutral endopeptidase. 2-Biphenyl- methylglutaric acid amide derivatives
TBA
15
Kelatorphan and related analogs: potent and selective inhibitors of leukotriene A4 hydrolase
TBA
34
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptides
TBA
12
4-Substituted proline derivatives that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11.
TBA
23
Mercaptoacyl dipeptides as dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Preliminary structure-activity studies
TBA
12
Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon
TBA
7
Structure-based design of dipeptide derivatives for the human neutral endopeptidase.
Kao
13
Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors.
Pfizer
17
Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
Cea
3
The synthesis of aminobenzazepinones as anti-phenylalanine dipeptide mimics and their use in nep inhibition
TBA
13
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by tricyclic benzazepinone thiols
TBA
7
Studies on the structural feature of S'1 subsite of neprilysin (EC.3.4.24.11): Stereochemical requirement for the enzyme-inhibitor docking process
TBA
5
Design and synthesis of a new class of conformationally constrained inhibitors to probe the active sites of thermolysine and neutral endopeptidase 24.11
TBA
14
α-Mercaptoacyl dipeptides that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11
TBA
2
Non-peptidic inhibitors of neutral endopeptidase 24.11 2. Design and pharmacology of orally active phosphonate prodrugs
TBA
26
Non-peptidic inhibitors of neutral endopeptidase 24.11 1. Discovery and optimization of potency
TBA
6
The effect of heteroatom substitution on a series of phosphonate inhibitors of neutral endopeptidase 24.11
TBA
6
Gem-cycloalkyl substituted thiol inhibitors of neutral endopeptidase 24.11. Synthesis via nucleophilic opening of 2,2-spiro-β-lactones
TBA
1
Synthesis of 6-amino-5-oxo-7-phenyl-1,4-oxazepines as conformationally constrained gauche (−) dipeptide mimetics
TBA
54
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
University of Athens
5
Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2.
Mount Sinai School of Medicine
6
Design of Novel Mercapto-3-phenylpropanoyl Dipeptides as Dual Angiotensin-Converting Enzyme C-Domain-Selective/Neprilysin Inhibitors.
University of Bath
9
A perspective on the development of small molecular neprilysin inhibitors (NEPi) with emphasis on cardiorenal disease.
Birla Institute of Technology and Sciences Pilani
24
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.
Glaxosmithkline
2
2-Aminothiophene scaffolds: Diverse biological and pharmacological attributes in medicinal chemistry.
Xinjiang Technical Institute of Physics and Chemistry
65
Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.
Vrije Universiteit Brussel
5
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.
Pfizer
10
A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years.
University of Electronic Science and Technology of China
47
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.
Pfizer
5
Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.
University of Cape Town
38
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
University of Nebraska Medical Center
21
N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
University of Paris
3
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.
British Biotech Pharmaceuticals
16
2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.
F. Hoffmann-La Roche
11
N-formyl hydroxylamine containing dipeptides: generation of a new class of vasopeptidase inhibitors.
Bristol Myers Squibb
6
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
University of Bath
8
Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.
The Bristol-Myers Squibb Pharmaceutical Research Institute
31
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Novartis Institutes For Biomedical Research
52
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Shionogi
16
Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.
Ciba-Geigy
12
Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.
Novartis Pharmaceuticals
19
Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
Bristol Myers Squibb
2
Synthesis and analgesic effects of N-[3-[(hydroxyamino) carbonyl]-1-oxo-2(R)-benzylpropyl]-L-isoleucyl-L-leucine, a new potent inhibitor of multiple neurotensin/neuromedin N degrading enzymes.
Ccipe-Faculté
16
Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.
University of Paris
5
Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11.
Marion Merrell Dow Research Institute
2
A mechanism-based inactivation study of neutral endopeptidase 24.11.
Salk Biotechnology/Industrial Associates
4
Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.
Ciba-Geigy
24
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
University of Paris
44
Mercaptoacyl amino acid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives.
Schering-Plough Research Institute
10
1H NMR configurational correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of"enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition.
TBA
14
New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties.
University of Paris
6
Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity.
Schering-Plough Research Institute
37
Substitutedα-mercaptoketones, new types of specific neprilysin inhibitors.
Pharmaleads
37
A novel class of enkephalinase inhibitors containing a C-terminal sulfo group.
Dainippon Pharmaceutical
6
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome.
Ranbaxy Laboratories
37
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
AstraZeneca
18
3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
Institute of Cancer Research
11
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
Stony Brook University
148
Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists
Takeda Pharmaceutical
19
Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
Merck Sharp & Dohme
1
N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function.
Novartis Pharma
54
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.
Virginia Commonwealth University